Edition:
India

ADMA Biologics Inc (ADMA.OQ)

ADMA.OQ on NASDAQ Stock Exchange Global Market

3.37USD
1:30am IST
Change (% chg)

$-0.01 (-0.30%)
Prev Close
$3.38
Open
$3.42
Day's High
$3.46
Day's Low
$3.32
Volume
887,800
Avg. Vol
667,897
52-wk High
$5.48
52-wk Low
$1.46

Latest Key Developments (Source: Significant Developments)

Adma Biologics Receives FDA Approval For License Transfers For Bivigam And Nabi-Hb
Monday, 8 Jul 2019 

July 8 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS RECEIVES FDA APPROVAL FOR LICENSE TRANSFERS FOR BIVIGAM AND NABI-HB.ADMA BIOLOGICS - FDA NOTIFIED LICENSES FOR BIVIGAM & NABI-HB REVOKED FROM BIOTEST PHARMACEUTICALS & TRANSFERRED, ISSUED TO CO'S U.S. LICENSE NO. 2019.  Full Article

ADMA Biologics Gets Patent for Treatment, Prevention of Pneumococcal Infections
Wednesday, 17 Apr 2019 

April 17 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS GRANTED U.S. PATENT FOR TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTIONS.ADMA BIOLOGICS INC - TERM OF PATENT EXTENDS TO MARCH 2037..  Full Article

ADMA Biologics Receives Department Of Health And Human Services U.S. License
Wednesday, 3 Apr 2019 

April 2 (Reuters) - ADMA Biologics Inc ::ADMA RECEIVES DEPARTMENT OF HEALTH AND HUMAN SERVICES U.S. LICENSE.ADMA BIOLOGICS INC - LICENSE AUTHORIZES ADMA TO MANUFACTURE AND ENTER INTO INTERSTATE COMMERCE WITH ASCENIV.ADMA BIOLOGICS INC - LICENSE COVERS BOCA RATON, FL MANUFACTURING FACILITY WHICH HAS DEMONSTRATED COMPLIANCE WITH FDA REQUIREMENTS.  Full Article

ADMA Biologics Submits Response And Provides Supplemental Information To FDA For Bivigam Complete Response Letter
Monday, 7 Jan 2019 

Jan 7 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS SUBMITS RESPONSE AND PROVIDES SUPPLEMENTAL INFORMATION TO FDA FOR BIVIGAM® COMPLETE RESPONSE LETTER.ADMA BIOLOGICS INC - ANTICIPATES RECEIVING AN ACKNOWLEDGEMENT LETTER FROM FDA WITHIN 30 DAYS.  Full Article

ADMA Biologics Says FDA declined to approve re-launch of Bivigam
Thursday, 20 Dec 2018 

Dec 19 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS PROVIDES REGULATORY UPDATE ON BIVIGAM® PAS SUBMISSIONS.ADMA BIOLOGICS INC - FDA ISSUES COMPLETE RESPONSE LETTER FOR PAS DRUG SUBSTANCE, APPROVES PAS FOR DRUG PRODUCT.ADMA BIOLOGICS INC - CRL DID NOT CONTAIN ANY REQUESTS FOR ADDITIONAL MANUFACTURING RUNS.ADMA BIOLOGICS INC - BELIEVES FDA COMMENTS TO DRUG SUBSTANCE PAS SUBMISSION ARE ADDRESSABLE AND RESOLVABLE.ADMA - FDA DIDN'T REQUEST ANY INFO PERTAINING TO COMPLIANCE STATUS, CLINICAL STUDY SAFETY, OTHERS ABOUT 3RD PARTY CONTRACT MANUFACTURERS AND VENDORS.ADMA BIOLOGICS INC - WILL REQUEST A MEETING WITH FDA AND PLANS TO PROMPTLY PROVIDE FDA WITH CLARIFICATION AND RESPONSES TO ISSUES RAISED IN CRL.  Full Article

Adma Biologics Q3 Loss Per Share $0.33
Friday, 9 Nov 2018 

ADMA Biologics Inc ::ADMA BIOLOGICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.33.Q3 EARNINGS PER SHARE VIEW $-0.31 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE $4.2 MILLION VERSUS I/B/E/S VIEW $4.7 MILLION.  Full Article

BRIEF-Adma Biologics Announces Commencement Of Operations, Initiation Of Collections At Its Adma Biocenters Plasma Collection Facility In Knoxville, TN

* ADMA BIOLOGICS -COMMENCEMENT OF OPERATIONS,INITIATION OF COLLECTIONS AT ITS NEWEST ADMA BIOCENTERS PLASMA COLLECTION FACILITY LOCATED IN KNOXVILLE,TN Source text for Eikon: Further company coverage: